Clinical trials

  • TEPROTUMUMAB for Thyroid eye disease (Graves' ophthalmopathy)
  • Onfekafusp alfa for Glioblastoma
  • CEFTRIAXONE for Viral lower respiratory tract infection | Viral pneumonia
  • ETOPOSIDE for Localized digestive neuroendocrine carcinoma
  • TRASTUZUMAB DERUXTECAN for Non-squamous non-small cell lung cancer | HER2 positive non-small cell lung cancer
  • Etoposide for Localized digestive neuroendocrine carcinoma
  • PRAX-628 for Focal epilepsy | Primary generalized tonic-clonic epilepsy
  • SODIUM IODIDE (131I) for Hyperthyroidism | Solitary hyperactive (hot) thyroid nodule
  • Durvalumab for Small cell lung cancer
  • RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE for Healthy volunteers|Neisseria meningitidis serogroup B vaccination
  • GOLCADOMIDE for Follicular lymphoma | Relapsed/refractory follicular lymphoma
  • Elsunersen (antisense oligonucleotide); sequence/chemical designation as listed in product record: 5'-MOEMC-(SP)-MOEMC-(P)-MOEA-(P)-MOEMC-(P)-MOEG-(P)-MOEA-(P)-DMC-(SP)-DA-(SP)-DT-(SP)-DA-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DMC-(SP)-MOET-(P)-MOEA-(SP)-MOEMC-(SP)-MOEA 3' for SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)